COMPARISON OF SERUM CA-72-4 AND CA-19-9 LEVELS IN GASTRIC-CANCER PATIENTS AND CORRELATION WITH RECURRENCE

被引：39

作者：

JOYPAUL, B

BROWNING, M

NEWMAN, E

BYRNE, D

CUSCHIERI, A

机构：

[1] NINEWELLS HOSP & MED SCH,DEPT SURG,DUNDEE DD1 9SY,SCOTLAND

[2] NINEWELLS HOSP & MED SCH,DEPT BIOCHEM MED,DUNDEE DD1 9SY,SCOTLAND

来源：

AMERICAN JOURNAL OF SURGERY | 1995年 / 169卷 / 06期

关键词：

D O I：

10.1016/S0002-9610(99)80228-1

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

BACKGROUND: This longitudinal prospective study evaluates the serum levels of the tumor markers CA 72-4 and CA 19-9, alone or in combination, in gastric cancer patients. PATIENTS AND METHODS: Serum tumor markers CA 72-4 and CA 19-9 were measured in 52 patients who had gastric adenocarcinomas and 32 with benign gastric disorders. Serial measurements of these markers were carried out in 30 cancer patients at a median follow-up time of 38 months. RESULTS: CA 72-4, and CA 19-9 had sensitivities of 42% and 46% for the preoperative detection of gastric cancer. Sensitivity for the two combined was 63%. CA 72-4 provided 100% specificity, compared to 72% for CA 19.9. Postoperatively, 17 cancer patients remained disease-free. Sixteen of these maintained normal levels of CA 72-4, and 10 of CA 19-9. Thirteen patients developed recurrent disease. in 9, serum CA 72-4 levels rose from near-normal after surgery and reached diagnostic values approximately 6 months before clinical diagnosis of recurrence. Only 3 patients exhibited such a pattern with CA 19-9, CONCLUSIONS: CA 72-4 is a reliable marker in gastric cancer. Postoperative serial sampling of CA 72-4 may facilitate early identification of recurrences.

引用

页码：595 / 599

页数：5

共 19 条

[1]

Guadagni F, Roselli M, Amato T, Et al., CA 72-4 measurement of tumor-associated glycoprotein (TAG-72) as a serum marker in the management of gastric cancer, Cancer Res, 52, pp. 1222-1227, (1992)

[2]

Heptner G, Domschke S, Domschke W, Comparison of CA 72-4 with CA 19-9 and carcinoembryonic antigen in the serodiagnosis of gastrointestinal malignancies, Scand J Gastroenterol, 24, pp. 745-750, (1989)

[3]

Byrne DJ, Browning MK, Cuschieri A, CA 72-4: a new tumor marker for gastric cancer, Br J Surg, 77, pp. 1010-1013, (1990)

[4]

Jalanko H, Kuusela P, Roberts P, Et al., Comparison of a new tumor-marker, CA 19-9 with alpha-fetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal diseases, J Clin Pathol, 37, pp. 218-222, (1984)

[5]

Guadagni F, Roselli M, Amato T, Et al., Tumor-associated glycoprotein-72 serum levels complement carcinoembryonic antigen levels in monitoring patients with gastrointestinal carcinoma, Cancer, 68, pp. 2443-2450, (1991)

[6]

Szymendera JJ, Szawlowski AW, Nowacki MP, Et al., Serum levels of carcinoembryonic antigen, gastrointestinal cancer antigen and alpha-fetoprotein in staging and management of patients with advanced carcinoma of the stomach, Int J Biol Markers, 2, pp. 19-24, (1987)

[7]

Staab HJ, Anderer FA, Brummendorf T, Et al., Prognostic value of preoperative serum CEA level compared to clinical staging: II. stomach cancer, Br J Cancer, 45, pp. 718-727, (1982)

[8]

Ritts RE, Del Villano BC, Go VL, Et al., Initial clinical evaluation of an immunoradiometric assay for CA 19-9 using the NCI serum bank, Int J Cancer, 33, pp. 339-345, (1984)

[9]

Gupta MK, Arciaga R, Bocci L, Et al., Measurement of a monoclonal-antibody-defined antigen (CA 19-9) in the sera of patients with malignant diseases: comparison with carcinoembryonic antigen, Cancer, 56, pp. 277-283, (1985)

[10]

Staab HJ, Hornung A, Anderer FA, Kieninger G, Clinical significance of the circulating tumor-associated antigen CA 19-9 in cancers of the digestive tract, Dtsch Med Wochenschr, 109, pp. 1141-1147, (1984)

← 1 2 →